Tacrolimus, also known as FK506, is a drug that causes immunosuppression and prevents transplant rejections. To achieve its effects, tacrolimus binds to FK506 Binding Protein (FKBP) creating a tacrolimus-FKBP complex. This complex then inhibits calcineurin, an enzyme important in the signalling for IL-2 production. By blocking IL-2 production, tacrolimus consequently results in reduced proliferation of all lymphocytes, but especially affects T-cells. Important side effects to note include neurotoxicity, nephrotoxicity, and hyperglycemia.
- Also called FK506
- Immunosuppressant drug
- Primarily used for transplant rejection prophylaxis
- Inhibits calcineurin by forming a complex with FK506-binding protein (FKBP)
- Results in reduced proliferation of all lymphocytes (e.g. T cells)
- Adverse Effects
- No gingival hyperplasia or hirsutism (contrast vs. Cyclosporine)